Prognostic variables in node-negative and node-positive breast cancer (eBook, PDF)
Redaktion: Gasparini, Giampietro
161,95 €
161,95 €
inkl. MwSt.
Sofort per Download lieferbar
81 °P sammeln
161,95 €
Als Download kaufen
161,95 €
inkl. MwSt.
Sofort per Download lieferbar
81 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
161,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
81 °P sammeln
Prognostic variables in node-negative and node-positive breast cancer (eBook, PDF)
Redaktion: Gasparini, Giampietro
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Zur Zeit liegt uns keine Inhaltsangabe vor.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 62.2MB
Andere Kunden interessierten sich auch für
- Advances in Breast Cancer Management (eBook, PDF)113,95 €
- Renal Cell Carcinoma (eBook, PDF)113,95 €
- Sentinel Node Biopsy in Breast Cancer (eBook, PDF)73,95 €
- Lymph Node Metastasis in Gastrointestinal Cancer (eBook, PDF)113,95 €
- Prognostic Factors in Cancer (eBook, PDF)73,95 €
- Triple-Negative Breast Cancer (eBook, PDF)65,95 €
- Non-Hodgkin Lymphoma (eBook, PDF)113,95 €
-
-
-
Zur Zeit liegt uns keine Inhaltsangabe vor.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Springer New York
- Seitenzahl: 428
- Erscheinungstermin: 6. Dezember 2012
- Englisch
- ISBN-13: 9781461551959
- Artikelnr.: 44179297
- Verlag: Springer New York
- Seitenzahl: 428
- Erscheinungstermin: 6. Dezember 2012
- Englisch
- ISBN-13: 9781461551959
- Artikelnr.: 44179297
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Prognostic variables in node-negative and node-positive breast cancer - Introduction.- Routinely available indicators of prognosis in breast cancer.- Prognostic factors for patients with breast cancers 1cm and smaller.- Steroid hormone receptors in breast cancer management.- S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer.- S-phase fraction and breast cancer - a decade of experience.- Prognostic and predictive value of thymidine labelling index in breast cancer.- Cyclin D1 in breast cancer.- Cyclins and breast cancer.- Prognostic implications of expression of the cell cycle inhibitor p27Kip1.- The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.- HER-2/neu as a predictive marker of response to breast cancer therapy.- Prognostic and predictive value of p53 and p21 in breast cancer.- The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.- Metalloproteinases and tissue inhibitors of metalloproteinases.- Matrix metalloproteinase inhibitors.- The 67 kDa laminin receptor as a prognostic factor in human cancer.- Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis.- Clinical significance of angiogenic factors in breast cancer.- Insulin-like growth factors in human breast cancer.- Molecular prognostic markers in breast cancer.- Prognostic significance of micrometastatic bone marrow involvement.- Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis.- Time-dependence of hazard ratios for prognostic factors in primary breast cancer.- Circulatingtumor markers in breast cancer: Accepted utilities and novel prospects.- The relationship between prognostic and predictive factors in the management of breast cancer.- Methodological challenges in the evaluation of prognostic factors in breast cancer.- Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?.- Prognostic variables in node-negative and node-positive breast cancer - editorial.- Author index.
Prognostic variables in node-negative and node-positive breast cancer - Introduction.- Routinely available indicators of prognosis in breast cancer.- Prognostic factors for patients with breast cancers 1cm and smaller.- Steroid hormone receptors in breast cancer management.- S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer.- S-phase fraction and breast cancer - a decade of experience.- Prognostic and predictive value of thymidine labelling index in breast cancer.- Cyclin D1 in breast cancer.- Cyclins and breast cancer.- Prognostic implications of expression of the cell cycle inhibitor p27Kip1.- The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.- HER-2/neu as a predictive marker of response to breast cancer therapy.- Prognostic and predictive value of p53 and p21 in breast cancer.- The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.- Metalloproteinases and tissue inhibitors of metalloproteinases.- Matrix metalloproteinase inhibitors.- The 67 kDa laminin receptor as a prognostic factor in human cancer.- Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis.- Clinical significance of angiogenic factors in breast cancer.- Insulin-like growth factors in human breast cancer.- Molecular prognostic markers in breast cancer.- Prognostic significance of micrometastatic bone marrow involvement.- Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis.- Time-dependence of hazard ratios for prognostic factors in primary breast cancer.- Circulatingtumor markers in breast cancer: Accepted utilities and novel prospects.- The relationship between prognostic and predictive factors in the management of breast cancer.- Methodological challenges in the evaluation of prognostic factors in breast cancer.- Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?.- Prognostic variables in node-negative and node-positive breast cancer - editorial.- Author index.